Neurocrine Initiates Phase 2 Study for NBI-1065890 in Tardive Dyskinesia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Source: Newsfilter
- Clinical Trial Launch: Neurocrine Biosciences has announced the initiation of its Phase 2 clinical study for NBI-1065890, planning to enroll approximately 100 adults with tardive dyskinesia to assess the drug's efficacy, safety, and tolerability.
- Drug Characteristics: NBI-1065890 is a selective VMAT2 inhibitor with distinct physical and chemical properties, potentially offering treatment options for a broader range of tardive dyskinesia patients, reflecting nearly 20 years of expertise in VMAT2 inhibition.
- Efficacy Assessment Metrics: The primary efficacy endpoint of the study is the change from baseline in the AIMS score at Week 8, aiming to scientifically validate the clinical value of the drug and enhance its market potential.
- Strategic Importance: Advancing this clinical trial is a key component of Neurocrine's strategy to define the future of VMAT2 biology and deliver lasting therapeutic impacts for patients, further solidifying its leadership position in the neuroscience field.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like NBIX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on NBIX
Wall Street analysts forecast NBIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBIX is 179.68 USD with a low forecast of 143.00 USD and a high forecast of 203.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 134.660
Low
143.00
Averages
179.68
High
203.00
Current: 134.660
Low
143.00
Averages
179.68
High
203.00
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Neurocrine Initiates Phase 2 Study for NBI-1065890 in Tardive Dyskinesia
- Clinical Trial Launch: Neurocrine Biosciences has announced the initiation of its Phase 2 clinical study for NBI-1065890, aiming to enroll approximately 100 adults with tardive dyskinesia to assess the drug's efficacy, safety, and tolerability, marking a strategic advancement in VMAT2 biology.
- Drug Characteristics: NBI-1065890 is a next-generation selective VMAT2 inhibitor with distinct physical and chemical properties that may provide treatment options for a broader range of tardive dyskinesia patients, reflecting the company's deep expertise and innovative capabilities in neuroscience.
- Efficacy Assessment Metrics: The primary efficacy endpoint of the study is the change from baseline in the AIMS score at Week 8, aiming to scientifically validate the clinical application potential of NBI-1065890, thereby delivering lasting positive impacts for patients.
- Market Outlook: Tardive dyskinesia affects at least 800,000 adults in the U.S., and the successful development of NBI-1065890 will further solidify Neurocrine's leadership position in the treatment of neuropsychiatric disorders, providing strong support for the company's future growth.
Continue Reading
Neurocrine Initiates Phase 2 Study for NBI-1065890 in Tardive Dyskinesia
- Clinical Trial Launch: Neurocrine Biosciences has announced the initiation of its Phase 2 clinical study for NBI-1065890, planning to enroll approximately 100 adults with tardive dyskinesia to assess the drug's efficacy, safety, and tolerability.
- Drug Characteristics: NBI-1065890 is a selective VMAT2 inhibitor with distinct physical and chemical properties, potentially offering treatment options for a broader range of tardive dyskinesia patients, reflecting nearly 20 years of expertise in VMAT2 inhibition.
- Efficacy Assessment Metrics: The primary efficacy endpoint of the study is the change from baseline in the AIMS score at Week 8, aiming to scientifically validate the clinical value of the drug and enhance its market potential.
- Strategic Importance: Advancing this clinical trial is a key component of Neurocrine's strategy to define the future of VMAT2 biology and deliver lasting therapeutic impacts for patients, further solidifying its leadership position in the neuroscience field.
Continue Reading